<?xml version="1.0" encoding="UTF-8"?>
<p>The last three decades have seen a dramatic rise in the use of monoclonal antibodies (mAbs) as therapeutics. By 2017, a total of 78 antibodies had been approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) [
 <xref rid="pntd.0007860.ref001" ref-type="bibr">1</xref>], with a further 11 approved by the FDA in 2018 [
 <xref rid="pntd.0007860.ref002" ref-type="bibr">2</xref>, 
 <xref rid="pntd.0007860.ref003" ref-type="bibr">3</xref>]. Beyond this, over 570 antibodies are in clinical development [
 <xref rid="pntd.0007860.ref004" ref-type="bibr">4</xref>]. The global mAb market reached US$100 billion annually in 2017 [
 <xref rid="pntd.0007860.ref005" ref-type="bibr">5</xref>], underscoring the considerable economic importance of these medicines.
</p>
